By Theo Marcell (editorial pen name) · Updated September 30, 2026 · We may have a financial affiliation with some entities featured on this page.
The short answer: Zepbound and Mounjaro both contain tirzepatide but have separate FDA labels. As of September 2026, Zepbound is labeled for long-term weight reduction and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is labeled for type 2 diabetes, including related cardiovascular risk reduction in certain adults.
People often ask whether Zepbound and Mounjaro are “the same thing.” The molecule is the same. The labels, the conditions each one is approved for, and the instructions that come with each one are not. This guide walks through those differences. It’s educational and isn’t medical advice. Which product, if any, fits a person is a conversation for a clinician who knows their history, labs, and other medications.
Are Zepbound and Mounjaro the same drug?
Both contain tirzepatide, a dual GIP and GLP-1 receptor agonist. That means it activates the receptors for two gut hormones that are involved in appetite, fullness, and blood sugar. Eli Lilly makes both brands.
What differs is the label. A brand name follows a prescribing label, and a label follows the conditions a manufacturer asked FDA to approve the product for. So the same molecule can carry one set of approved uses under one brand name and a different set under another. Our guide to the semaglutide vs tirzepatide comparison covers how tirzepatide differs from semaglutide, and Wegovy vs Ozempic covers the equivalent brand pair on the semaglutide side.
What is each brand approved for?
The table below is a high-level summary from the current FDA prescribing information on DailyMed as of September 2026. Labels change, so check the current label for the exact product.
| Brand | Labeled uses as of September 2026 (high level) |
|---|---|
| Zepbound | With a reduced-calorie diet and increased physical activity: reducing excess body weight and maintaining the reduction long term in adults with obesity, or in adults with overweight and at least one weight-related condition; treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. |
| Mounjaro (label revised 8/2026) | Improving blood sugar control, with diet and exercise, in adults and in children 10 years and older with type 2 diabetes; reducing the risk of major cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events. |
A few points are worth underlining:
- Zepbound’s label covers weight reduction and sleep apnea. It does not list type 2 diabetes.
- Mounjaro’s label covers type 2 diabetes and related cardiovascular risk reduction. It does not list weight reduction or sleep apnea.
- A label describes approved uses, not what a clinician may discuss. Clinicians can prescribe an approved drug for a use not listed on its label (“off-label”). That is a judgment between a patient and a prescriber, and it isn’t something this page recommends.
What evidence sits behind the sleep apnea label?
The OSA indication is the newest difference between the two brands. According to FDA’s announcement of the approval, it rests on two randomized, double-blind, placebo-controlled studies in 469 adults with obesity and moderate to severe OSA who did not have type 2 diabetes. One study enrolled people using positive airway pressure (PAP) therapy, and the other enrolled people who were unable or unwilling to use it. Participants received tirzepatide or placebo once weekly for 52 weeks.
FDA reported that, compared with placebo, people receiving Zepbound had a statistically significant reduction in the apnea-hypopnea index, which counts breathing pauses and shallow breaths per hour of sleep, and that they also lost more body weight. FDA noted the improvement in OSA is likely related to the weight reduction. These are trial results for the populations studied and do not predict any one person’s outcome.
How do the labels describe dosing and presentations?
This section is about reading the labels, not choosing a dose.
- Frequency: Both are once-weekly injections.
- Gradual increases: Each label describes starting at a low dose and increasing gradually in steps. Your clinician determines the dose, including whether and when it changes.
- Different indications, different dosing instructions: The Zepbound label gives its own maintenance dosing language for weight reduction and for OSA, and the Mounjaro label gives its own for type 2 diabetes. The instructions are not interchangeable between the two.
- Presentations: The labels list several presentations, including single-dose pens, single-dose vials, multi-dose vials, and multi-dose KwikPens that hold four doses. Labels say patients and caregivers should be trained on the specific presentation they receive, and should consult the Instructions for Use again if the presentation changes. The Zepbound label also says its KwikPen isn’t recommended for self-administration by people who are visually impaired.
The Medication Guide and Instructions for Use for the exact product are the reference, and a pharmacist can walk through them.
How do the risks and warnings compare?
Because the molecule is the same, the core safety information overlaps heavily. Both labels carry a boxed warning about thyroid C-cell tumors seen in rats, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Both labels also describe warnings that include severe gastrointestinal reactions (the Zepbound label says it isn’t recommended in people with severe gastroparesis), acute kidney injury from dehydration, acute gallbladder disease, and acute pancreatitis. This is not a complete list, so read the full label for the product in question.
Coadministration is also addressed. The Zepbound label says using it with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended. Since Mounjaro also contains tirzepatide, the two brands aren’t meant to be combined.
What tends to shape the choice?
These are themes people often raise with their clinicians. They aren’t recommendations.
- Labeled use: Is the goal tied to type 2 diabetes, weight reduction, or sleep apnea? Each maps to a different label.
- Coverage: Plans often consider the labeled indication along with their own rules, so the same molecule can be treated differently depending on the brand and diagnosis. Coverage, prior authorization, and cash prices vary by plan, employer, and state, and they change often. Your plan and pharmacy have current details.
- Presentation and practical factors: Pen, vial, or KwikPen, other medications, pregnancy plans, GI history, and diabetes complications often matter as much as pharmacology.
For how tirzepatide’s trial results compare with semaglutide’s, see our plain-English guide to the STEP, SURMOUNT, and SELECT trials.
Key takeaways
- Zepbound and Mounjaro both contain tirzepatide but have separate labels.
- As of September 2026, Zepbound is labeled for weight reduction and moderate to severe OSA in adults with obesity. Mounjaro is labeled for type 2 diabetes (adults and children 10 and older) and for reducing cardiovascular risk in certain adults with type 2 diabetes.
- Both are once-weekly injections whose labels describe gradual dose increases. Your clinician determines the dose.
- Both carry a boxed warning about thyroid C-cell tumors seen in rats.
- The brands aren’t meant to be combined with each other or with other GLP-1 receptor agonists.
FAQ
Is Zepbound just a higher dose of Mounjaro? No. They’re separate products with separate labels, indications, and dosing instructions. Dose strength is only one of the differences.
Can you take Zepbound and Mounjaro together? The Zepbound label says coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist isn’t recommended. Decisions about this belong to your prescribing clinician.
Is Mounjaro approved for weight loss? No. As of September 2026, the Mounjaro label covers improving blood sugar control in type 2 diabetes and reducing cardiovascular event risk in adults with type 2 diabetes at high risk. It does not list weight reduction. Zepbound carries the weight-reduction indication.
Is Zepbound approved for type 2 diabetes? No. The Zepbound label lists weight reduction and obstructive sleep apnea in adults with obesity. Mounjaro carries the type 2 diabetes indication.
Are these medicines safe for everyone? No medicine is. Both carry a boxed warning about thyroid C-cell tumors seen in rats and other warnings listed in their prescribing information.
This article is for general education and isn’t medical advice. Talk with a licensed clinician before starting, stopping, or changing any medication.
We may have a financial affiliation with some entities featured on this page.
References
- Zepbound prescribing information (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- Mounjaro prescribing information (DailyMed, revised 8/2026): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- FDA, “FDA Approves First Medication for Obstructive Sleep Apnea”: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea